#1
#1 out of 1
health22h ago
Moderna gets $50 million to develop mRNA Ebola vaccine against Bundibugyo
- CEPI pledged up to $50 million to Moderna for preclinical work and Phase 1 testing of its BDBV mRNA vaccine.
- CEPI will also fund other groups to develop vaccines using similar platforms against Bundibugyo.
- The Bundibugyo outbreak in the DRC fuels urgency for vaccines specific to this strain.
- Moderna’s vaccine leverages its mRNA platform to enable rapid development for emerging threats.
- CEPI’s broader funding supports vaccine development efforts alongside Moderna.
- No licensed therapeutics exist specifically for Bundibugyo yet.
- Outbreak conditions include armed conflict and large population movement in the DRC.
- WHO reports over 1,000 cases and more than 200 deaths in the Bundibugyo outbreak.
- CEPI’s funding also supports vaccine development at Oxford and Serum Institute of India.
- Two licensed Ebola vaccines currently target the Zaire strain, not Bundibugyo.
Vote 0